Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. 2007

Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
Department of Drug Metabolism and Pharmacokinetics, Johnson and Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica N.V., Beerse, Belgium.

The pharmacokinetic-pharmacodynamic (PK-PD) correlation of the effect of fluvoxamine on para-chloroamphetamine (PCA)-induced behavior was determined in the rat. Rats (n=66) with permanent arterial and venous cannulas received a 30-min intravenous infusion of 1.0, 3.7 or 7.3 mg kg(-1) fluvoxamine. At various time points after the start of fluvoxamine administration, a single dose of PCA (2.5 mg kg(-1)) was injected in the tail vein and resulting behavioral effects, excitation (EXC), flat body posture (FBP) and forepaw trampling (FT), were immediately scored (scores: 0, 1, 2 or 3) over a period of 5 min. In each individual animal the time course of the fluvoxamine plasma concentration was determined up to the time of PCA administration. Observed behavioral effects were related to fluvoxamine plasma concentrations. Fluvoxamine pharmacokinetics was described by a population three-compartment pharmacokinetic model. The effects of fluvoxamine on PCA-induced behavior (probability of EXC, FBP and FT) were directly related to fluvoxamine plasma concentration on the basis of the proportional odds model. For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively. Slightly higher EC(50) values were obtained for the corresponding effects on FBP and FT. This investigation demonstrates the feasibility of PK-PD modeling of categorical drug effects in animal behavioral pharmacology. This constitutes a basis for the future development of a mechanism-based PK-PD model for fluvoxamine in this paradigm.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010133 p-Chloroamphetamine Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool. p-Chloramphetamine,para-Chloroamphetamine,LY-121860,Ly-123362,Parachloroamphetamine,LY 121860,LY121860,Ly 123362,Ly123362,p Chloramphetamine,p Chloroamphetamine,para Chloroamphetamine
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D016666 Fluvoxamine A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. DU-23000,Desiflu,Dumirox,Faverin,Fevarin,Floxyfral,Fluvoxadura,Fluvoxamin AL,Fluvoxamin Stada,Fluvoxamin beta,Fluvoxamin-neuraxpharm,Fluvoxamin-ratiopharm,Fluvoxamina Geminis,Fluvoxamine Maleate,Fluvoxamine Maleate, (E)-Isomer,Fluvoxamine, (Z)-Isomer,Luvox,Novo-Fluvoxamine,Nu-Fluvoxamine,PMS-Fluvoxamine,ratio-Fluvoxamine,DU 23000,DU23000,Fluvoxamin neuraxpharm,Fluvoxamin ratiopharm,Geminis, Fluvoxamina,Novo Fluvoxamine,Nu Fluvoxamine,PMS Fluvoxamine,ratio Fluvoxamine
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
January 2006, Journal of pharmacological and toxicological methods,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
April 2021, Journal of affective disorders,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
January 2000, Archives of medical research,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
June 1978, Annals of the New York Academy of Sciences,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
January 1996, Methods and findings in experimental and clinical pharmacology,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
July 1999, Anesthesiology,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
August 2003, Journal of pharmaceutical sciences,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
May 1984, The Journal of pharmacology and experimental therapeutics,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
May 2005, Journal of pain and symptom management,
Marian Geldof, and Jan Freijer, and Ludy van Beijsterveldt, and Patrick C M Vermote, and Anton A Megens, and Meindert Danhof
February 1997, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!